Considering PAD, there is only one previous study in the literature evaluating the expression of CD64 on PMN in CVID patients, suggesting that a high CD64 expression is associated with a worse prognosis and outcome [7]. The gene discussed is FCGR1A; the disease is peripheral arterial disease.